A drug that inhibits the Notch signalling process is active in a range of advanced cancers

(ECCO-the European CanCer Organisation) A new anti-cancer drug that inhibits a key cell signalling process involved in many different cancers has shown that it is capable of stopping the progression of cancer and shrinking tumors; importantly, in rare, less well-studied cancers such as adenoid cystic carcinoma. Dr. Christophe Massard told the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics that the drug LY3039478 was successful in inhibiting the Notch signalling pathway in patients with alterations in the Notch protein.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news